This January we were treated to a mix of novel psychedelic trials and an unusually large amount of re-analyses of earlier studies. Ibogaine was researched

A Phase II trial affirmed the safety and efficacy of psilocybin-assisted therapy in a group setting, with a majority experiencing sustained response and remission from

This November, promising developments emerged across various areas of psychedelic research. To start, an innovative study explored novel routes of administering ayahuasca-analogue compounds, potentially improving

This October, we saw two significant psychedelic studies being published that were previously released as pre-prints. The first is concerned with the extended DMT trial

In September 2023, the second Phase III study from MAPS was published, showing more than two-thirds of those treated with MDMA-assisted psychotherapy no longer met